Compare Heron Therapeutics Inc (HRTX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.48 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 1076.3× Heron Therapeutics Inc's market cap, and Vanguard Sht-Term Inflation-Protected Sec Idx ETF is more actively traded (2,511,360 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| HRTX | VTIP | |
|---|---|---|
Market Cap | $68.01M | $73.20B |
Volume | 1,891,941 | 2,511,360 |
Sector | Health | — |
52-Week High | $1.49 | $50.46 |
52-Week Low | $0.27 | $48.38 |
Typical Hold Time | 35 Days | 91 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
VTIP trades at $48.46, showing minimal daily movement with a slight decline of 0.01%. Technical indicators present a mixed picture with bearish moving averages but bullish oscillators, including oversold RSI readings. The ETF focuses on short-term inflation-protected securities, offering protection against rising inflation while minimizing interest rate sensitivity. Recent institutional activity shows increased positions from firms like NewEdge Advisors and 55 North Private Wealth.
The outlook for VTIP remains tied to inflation dynamics and Federal Reserve policy. With inflation persisting above the 2% target, short-duration TIPS provide strategic hedging value. However, the fund faces risks from potential Fed policy shifts and real yield fluctuations. Current technical weakness suggests near-term pressure, but oversold conditions may present entry opportunities for inflation-conscious investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
